References from scientific journals

Ketorolac tromethamine - routes and clinical implications.

Vadivelu N, Gowda AM, Urman RD, Jolly S, Kodumudi V, Maria M, Taylor R Jr, Pergolizzi JV Jr. Vadivelu N, et al. Pain Pract. 2015 Feb;15(2):175-93. doi: 10.1111/papr.12198. Epub 2014 Apr 16. Pain Pract. 2015. PMID: 24738596 Review.

Over the last 20 years, numerous studies have been conducted involving ketorolac. These studies have provided additional information about various routes of administration and their effect on the efficacy and the side effect profile of ketorolac. Moreover, ketoro …
Over the last 20 years, numerous studies have been conducted involving ketorolac. These studies have provided additional information …

Comparison of Intravenous Ketorolac at Three Single-Dose Regimens for Treating Acute Pain in the Emergency Department: A Randomized Controlled Trial.

Motov S, Yasavolian M, Likourezos A, Pushkar I, Hossain R, Drapkin J, Cohen V, Filk N, Smith A, Huang F, Rockoff B, Homel P, Fromm C. Motov S, et al. Ann Emerg Med. 2017 Aug;70(2):177-184. doi: 10.1016/j.annemergmed.2016.10.014. Epub 2016 Dec 16. Ann Emerg Med. 2017. PMID: 27993418 Clinical Trial.

STUDY OBJECTIVE: Nonsteroidal anti-inflammatory drugs are used extensively for the management of acute and chronic pain, with ketorolac tromethamine being one of the most frequently used parenteral analgesics in the emergency department (ED). ...We evaluate the anal …
STUDY OBJECTIVE: Nonsteroidal anti-inflammatory drugs are used extensively for the management of acute and chronic pain, with ketorolac …

DDX3 modulates cisplatin resistance in OSCC through ALKBH5-mediated m6A-demethylation of FOXM1 and NANOG.

Shriwas O, Priyadarshini M, Samal SK, Rath R, Panda S, Das Majumdar SK, Muduly DK, Botlagunta M, Dash R. Shriwas O, et al. Apoptosis. 2020 Apr;25(3-4):233-246. doi: 10.1007/s10495-020-01591-8. Apoptosis. 2020. PMID: 31974865

In this study we found genetic (shRNA) or pharmacological (ketorolac salt) inhibition of DDX3 reduced CSC population by suppressing the expression of FOXM1 and NANOG. ...In a patient-derived cell xenograft model of chemoresistant OSCC, ketorolac salt restores cispla …
In this study we found genetic (shRNA) or pharmacological (ketorolac salt) inhibition of DDX3 reduced CSC population by suppressing t …

Efficacy of topical ketorolac tromethamine 0.4% for control of pain or discomfort associated with cataract surgery.

Price MO, Price FW. Price MO, et al. Curr Med Res Opin. 2004 Dec;20(12):2015-9. doi: 10.1185/030079904x16759. Curr Med Res Opin. 2004. PMID: 15701218 Clinical Trial.

OBJECTIVE: To evaluate the efficacy of ketorolac 0.4% ophthalmic solution for control of pain and discomfort associated with cataract surgery. ...RESULTS: Patients reported significantly less ocular pain during the 24 h following surgery when treated with ketorolac …
OBJECTIVE: To evaluate the efficacy of ketorolac 0.4% ophthalmic solution for control of pain and discomfort associated with cataract …

Ketorolac tromethamine 0.4% as a treatment for allergic conjuctivitis.

Schechter BA. Schechter BA. Expert Opin Drug Metab Toxicol. 2008 Apr;4(4):507-11. doi: 10.1517/17425255.4.4.507. Expert Opin Drug Metab Toxicol. 2008. PMID: 18433352 Review.

BACKGROUND: Acular LS (ketorolac tromethamine 0.4%) ophthalmic solution, a reformulation of the original Acular (ketorolac tromethamine 0.5%), is indicated for the reduction of ocular pain and burning/stinging following corneal refractive surgery. ...R …
BACKGROUND: Acular LS (ketorolac tromethamine 0.4%) ophthalmic solution, a reformulation of the original Acular (ketorolac …

Comparison of intravenous ketorolac at three doses for treating renal colic in the emergency department: A noninferiority randomized controlled trial.

Eidinejad L, Bahreini M, Ahmadi A, Yazdchi M, Thiruganasambandamoorthy V, Mirfazaelian H. Eidinejad L, et al. Acad Emerg Med. 2021 Jul;28(7):768-775. doi: 10.1111/acem.14202. Epub 2021 Feb 17. Acad Emerg Med. 2021. PMID: 33370510 Clinical Trial.

BACKGROUND: Ketorolac tromethamine is a nonsteroidal anti-inflammatory drug (NSAID) that is extensively used for the management of renal colic in the emergency department (ED). It has been proposed that ketorolac is used at doses above its analgesic ceiling w …
BACKGROUND: Ketorolac tromethamine is a nonsteroidal anti-inflammatory drug (NSAID) that is extensively used for the managemen …

An update on the use of ophthalmic ketorolac tromethamine 0.4%.

Perry HD, Donnenfeld ED. Perry HD, et al. Expert Opin Pharmacother. 2006 Jan;7(1):99-107. doi: 10.1517/14656566.7.1.99. Expert Opin Pharmacother. 2006. PMID: 16370927 Review.

Ketorolac tromethamine 0.4% ophthalmic solution, a recent reformulation of the original ketorolac tromethamine 0.5% solution, is indicated for the reduction of ocular pain and burning/stinging following cataract and refractive surgery. Studies have dem …
Ketorolac tromethamine 0.4% ophthalmic solution, a recent reformulation of the original ketorolac tromethamine 0 …

Preoperative ketorolac tromethamine 0.4% in phacoemulsification outcomes: pharmacokinetic-response curve.

Donnenfeld ED, Perry HD, Wittpenn JR, Solomon R, Nattis A, Chou T. Donnenfeld ED, et al. J Cataract Refract Surg. 2006 Sep;32(9):1474-82. doi: 10.1016/j.jcrs.2006.04.009. J Cataract Refract Surg. 2006. PMID: 16931258 Clinical Trial.

PURPOSE: To assess the clinical benefit, relative efficacy, and pharmacokinetic-response curve of preoperative and postoperative ketorolac tromethamine 0.4% (Acular LS) to improve outcomes during and after cataract surgery. ...CONCLUSION: The preoperative use of …
PURPOSE: To assess the clinical benefit, relative efficacy, and pharmacokinetic-response curve of preoperative and postoperative ketorola …

Ketorolac tromethamine.

Jay GT. Jay GT. Conn Med. 1991 May;55(5):288-90. Conn Med. 1991. PMID: 1860314 Review. No abstract available.


Ketorolac, an injectable nonnarcotic analgesic.

Litvak KM, McEvoy GK. Litvak KM, et al. Clin Pharm. 1990 Dec;9(12):921-35. Clin Pharm. 1990. PMID: 2292174 Review.

Ketorolac tromethamine has been administered concomitantly with morphine or meperidine without apparent adverse interaction. For short-term pain management, an initial i.m. ketorolac tromethamine loading dose of 30 or 60 mg is recommended. ...
Ketorolac tromethamine has been administered concomitantly with morphine or meperidine without apparent adverse interaction. F …